SLC5A2 and type 2 diabetes mellitus: Despite having the shortest elimination half-life (5.29±0.508 h) of all SGLT2 inhibitors available in Japan [13,14], tofogliflozin administration has been reported not to be inferior with regard to improving blood glucose and HbA1c levels in patients with type 2 diabetes [14].